Journal
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
Volume 6, Issue 3, Pages 88-100Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1758834013519843
Keywords
biomarkers; targeted therapy; triple-negative breast cancer
Categories
Funding
- NCI NIH HHS [K23 CA172691] Funding Source: Medline
Ask authors/readers for more resources
Triple-negative breast cancer (TNBC) represents a challenge clinically due to a lack of response to hormonal and HER2-targeted agents coupled with an aggressive disease course. As the biology of this breast cancer subtype is better understood, it is clear that TNBC is a heterogeneous disease and one targeted therapy is unlikely to be active in all patients. Biomarkers predictive of response to treatment are thus of great importance in TNBC. This review outlines studies evaluating biomarkers predictive of response to neoadjuvant chemotherapy and to targeted therapies in the advanced setting. The development of validated biomarkers in conjunction with novel targeted therapies represents an opportunity to improve patient outcomes in TNBC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available